Showcasing KRas Degrader-Antibody Conjugates as a Therapeutic Approach for Treating KRas Driven Colorectal Cancer

• Exploring how KRas degraders offer more complete KRas inhibition compared to small molecule inhibitors.
• Showing how KRas degrader-Certuximab conjugate has unique advantages in treating KRas driven colorectal cancer
• Highlighting Polymed’s KRas degrader and degrader-antibody conjugates demonstrated preclinical proof-of-concept

Speakers:

Lan Xu

Senior Vice President - Translational Medicine

Polymed Biopharmaceuticals